Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 7, 2014La nuova tecnologia consente di affrontare patologie cardiache complesse che colpiscono in Europa 1,2 milioni di pazienti
I primi impianti, effettuati in questo periodo con la collaborazione di medici specialisti europei, hanno avuto risultati positivi e hanno consentito all’équipe medica di acquisire competenze...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Oct 2, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Sep 29, 2014
New data for the Lotus™ Valve System announced at PCR London Valves 30-Day outcomes for the 250 patients enrolled in REPRISE II Extended Cohort trial were presented by Prof Ian Meredith at PCR...
-
Sep 29, 2014Neue Daten für das Lotus™-Klappensystem beim PCR London Valves Kongress vorgestellt
Prof. Ian Meredith hat im Rahmen des PCR London Valves Kongresses am Montag 30-Tage-Daten der REPRISE-II-Extension vorgestellt, die 250 Patienten einschließt. REPRISE II, eine Studie zur...
-
Sep 25, 2014Nuovi dati per la valvola Lotus™ presentati al congresso PCR London Valves
I dati a 30 giorni per i 250 pazienti arruolati nello studio di coorte esteso REPRISE II sono stati presentati il 29 settembre dal Professor Ian Meredith nell'ambito del congresso PCR London...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 18, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 15, 2014Auch nach einem Jahr keine Fälle von moderater oder schwerer paravalvulärer Aorteninsuffizienz
Neue Daten aus dem klinischen Studienprogramm zum Lotus™-Klappensystem der Boston Scientific Corporation (NYSE: BSX) belegen weiterhin die gute Wirksamkeit und Einsatzmöglichkeit des Devices...
-
Aug 30, 2014
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Jul 11, 2014
Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently,...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific begrüßt die neuen Leitlinien des „National Institute for Health and Care Excellence“ (NICE) zum Einsatz von implantierbaren Kardioverter-Defibrillatoren (ICD) und Geräten...
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman. ATTENZIONE:...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman.
-
Jun 13, 2014
In einer kurzen Video-Zusammenfassung zum EuroPCR-Kongress präsentieren Dr. Keith G. Oldroyd und Dr. Daniel Blackman die neuesten klinischen Daten der EVOLVE- und REPRISE-II-Studie....
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman. DISCLAIMER: Please be...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.
-
Jun 13, 2014
In einer kurzen Video-Zusammenfassung zum EuroPCR-Kongress präsentieren Dr. Keith G. Oldroyd und Dr. Daniel Blackman die neuesten klinischen Daten der EVOLVE- und REPRISE-II-Studie....
-
Jun 12, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
May 29, 2014I dati dello studio EVOLVE presentati nell'ambito dell’EuroPCR 2014 hanno dimostrato un eccellente profilo di sicurezza
Boston Scientific Corporation (NYSE: BSX) ha riportato dati positivi di follow-up a tre anni dello studio clinico EVOLVE, che confronta la sicurezza e la performance di SYNERGY™, stent...
-
May 27, 2014Solo l'1,1% dei pazienti ha manifestato rigurgito aortico paravalvolare moderato; non si sono verificati casi severi
Con un'ulteriore conferma della sua tecnologia avanzata per l'impianto transcatetere della valvola aortica (TAVI), il dispositivo Lotus?, di Boston Scientific Corporation (NYSE: BSX), continua a...
-
May 22, 2014Los datos del estudio EVOLVE, presentados hoy en EuroPCR 2014, muestran además un excelente perfil de seguridad.
Boston Scientific Corporation (NYSE: BSX) ha anunciado datos de seguimiento a los tres años del estudio clínico EVOLVE, en el que se comparan la eficacia y el rendimiento del stent coronario...
-
May 22, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014Die Daten der EVOLVE-Studie, die heute im Rahmen der EuroPCR präsentiert wurden, belegen außerdem ein exzellentes Sicherheitsprofil
Boston Scientific Corporation (NYSE: BSX) hat positive Dreijahres-Daten aus der klinischen Studie EVOLVE präsentiert, in der Sicherheit und Leistung des Everolimus freisetzenden und mit...
-
May 21, 2014EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the safety and performance of the SYNERGY™ Everolimus-Eluting...
-
May 21, 2014
Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred Further validating its advanced transcatheter aortic valve implantation (TAVI)...
-
May 16, 2014Patients In Germany Receive New Transcatheter Aortic Valve Implantation Devices Specially Designed For Total Control And Accurate Deployment
Marking a major step forward in the evolution of Transcatheter Aortic Valve Implantation (TAVI) technology, the first two commercial implants of the Boston Scientific (NYSE: BSX) Lotus™ Valve...
-
May 16, 2014
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...
-
May 8, 2014Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...
-
May 8, 2014
Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision...
-
May 8, 2014Advanced Illumina™ 3D Programming Software Provides Highly Significant Pain Relief in Study Patients
New retrospective data highlighting the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate the device provided sustained and highly...
-
Apr 24, 2014Nel 2013 aumentati più del 50% gli impianti di “ombrellini salvacuore”che riducono il rischio ictus del 77%
Milano, 23 Aprile 2014 - Ogni anno, in Italia, 200mila persone vengono colpite da ictus, con un impatto pesantissimo sulle famiglie, sia dal punto di vista sociale che economico. Si stima che nel...